Latest filing published 26 May 2020 for Quotient Ltd.
Insider track record
Closed purchases
Based on 12 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -19.2%Entry US$38.81 · Close at T+365 US$31.34
- -3.0%Entry US$40.64 · Close at T+365 US$39.43
- +8.6%Entry US$35.72 · Close at T+365 US$38.81
- +40.2%Entry US$28.70 · Close at T+365 US$40.22
- +6.2%Entry US$33.63 · Close at T+365 US$35.72
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Christopher J. Lindop: trading record in brief
Christopher J. Lindop has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Haemonetics Corp, Parexel International Corp and Quotient Ltd. We count 125 filings; the first trade dates from 1 November 2006 and the latest from 24 May 2020.
In open-market terms, that means 15 purchases worth €139k on one side and 29 sales worth €10.9M on the other. Taken together, the sales exceed the purchases by €10.7M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 24 share grants and 18 option exercises.
A typical purchase (the median) is worth €8,212. After 12 purchases with a full 90-day history, the hit rate stands at 67% and the median 90-day move at +2.3%. These figures describe past trades and do not predict future prices.
The latest filing, published on 26 May 2020, reports an option exercise in Quotient Ltd. The most recent open-market purchase was published on 2 May 2013, 4,938 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Christopher J. Lindop
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 25,271 sharesOrdinary SharesSEC:0000899243-20-014208:0
- 58,334 sharesOrdinary SharesSEC:0000899243-20-003982:0
- 21,446 sharesOrdinary SharesSEC:0000899243-19-014844:0
- 58,333 sharesOrdinary SharesSEC:0000899243-19-003335:0
- 52,465 shares@ US$5.8055.5% of flowOrdinary SharesSEC:0000899243-18-020209:0
- 58,333 sharesOrdinary SharesSEC:0000899243-18-003709:0
- 52,465 shares@ US$4.6427.2% of flowOrdinary SharesSEC:0000899243-17-024901:0
- 19,597 sharesCommon StockSEC:0000899243-17-023621:0
- 2,850 shares0Common StockSEC:0001127602-17-027249:0
- 1,823 shares0Common StockSEC:0001127602-17-027249:1
- 50,000 shares@ US$6.4138.9% of flowOrdinary SharesSEC:0000899243-17-003789:0
- 2,369 shares0Common StockSEC:0001127602-16-062577:0
- 2,000 shares@ US$60.28100.0% of flowCommon StockSEC:0001127602-16-044674:0
- 11,393 sharesCommon StockSEC:0001127602-16-037241:0
- 436 shares@ US$32.13Common StockSEC:0001127602-15-029697:0
- 6,255 shares@ US$0.01Common StockSEC:0001127602-15-029498:0
- 2,420 shares0Common StockSEC:0001127602-15-026862:0
- 4,902 shares@ US$26.32Common StockSEC:0000313143-15-000079:0
- 4,902 shares@ US$38.49Common StockSEC:0000313143-15-000079:1
- 4,902 shares@ US$26.32Common StockSEC:0000313143-15-000050:0
- 4,902 shares@ US$39.09Common StockSEC:0000313143-15-000050:1
- 4,902 shares@ US$26.32Common StockSEC:0000313143-15-000044:0
- 4,902 shares@ US$42.51Common StockSEC:0000313143-15-000044:1
- 4,902 shares@ US$26.32Common StockSEC:0000313143-15-000030:0
- 4,902 shares@ US$41.65Common StockSEC:0000313143-15-000030:1
25 of 124 declarations
